Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis.
Loading...
Type
Article
Change log
Authors
Abstract
Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.
Description
Keywords
antivirals, favipiravir, human norovirus, interferon λ, lethal mutagenesis, polymerase, protease, Antiparasitic Agents, Antiviral Agents, Caliciviridae Infections, Gastroenteritis, Humans, Mutagenesis, Nitro Compounds, Norovirus, Thiazoles, Viral Vaccines, Virus Replication
Journal Title
J Infect Dis
Conference Name
Journal ISSN
0022-1899
1537-6613
1537-6613
Volume Title
213
Publisher
Oxford University Press (OUP)
Publisher DOI
Sponsorship
Wellcome Trust (097997/Z/11/Z)
Wellcome Trust (100891/Z/13/Z)
Wellcome Trust (100891/Z/13/Z)
The authors declare no conflict in interest. This work was supported by the Wellcome Trust (Ref: WT097997MA)